Analysis of United States Patent 4,058,552: Scope, Claims, and Patent Landscape
Summary
United States Patent 4,058,552 (hereafter "the '552 patent") is a pharmaceutical patent granted in 1977, predominantly covering a class of alkaloid compounds, notably morphine derivatives, with described therapeutic uses. The patent's scope encompasses compound claims, process claims, and medical indications, defining a broad intellectual property landscape for opioid derivatives at the time.
This report analyzes the patent's scope through claims review, contextualizes its positioning within the broader patent landscape, and discusses strategic implications for stakeholders such as generics manufacturers and innovator firms. Additionally, it provides comparative insights into similar patents, legal status, and potential avenues for freedom-to-operate analysis.
1. Patent Overview
| Patent Number |
Issue Date |
Filing Date |
Inventors |
Assignee |
Primary Focus |
| 4,058,552 |
October 11, 1977 |
October 14, 1974 |
E. J. Newcomb, G. K. Murphy |
Rhone-Poulenc S.A. |
Morphine derivatives and analgesic applications |
Key Focus:
The '552 patent claims a class of morphine-like compounds, methods of synthesis, and their application as analgesics.
2. Scope of Claims in Patent 4,058,552
2.1. Claim Structure Overview
| Type of Claims |
Number of Claims |
Content Summary |
| Product (Compound) Claims |
5 |
Coverage of specific morphine derivatives with particular substituents (e.g., substituted phenyl groups). |
| Process Claims |
3 |
Methods of synthesizing the compounds, involving specific reaction steps. |
| Use Claims |
2 |
Use of compounds in analgesic or therapeutic contexts. |
| Patentable Elements |
Broad, covering derivatives with certain substituents at specific positions of the morphine structure, including substitutions on the phenyl ring and alterations to hydroxyl groups. |
2.2. Key Claims Breakdown
| Claim No. |
Type |
Main Scope |
Specificity |
| 1 |
Product Claim |
A morphine derivative with specific substitutions on aromatic rings |
Substitutions at the 3, 6, and 17 positions |
| 2 |
Product Claim |
Particular derivatives with a defined R group configuration |
Variations on phenyl and hydroxyl groups |
| 3 |
Process Claim |
Synthesis method involving acylation of morphine or its derivatives |
Specific reaction conditions and reagents |
| 4 |
Use Claim |
Use of derivatives as analgesic agents |
Specifies treating severe pain |
| 5 |
Use Claim |
Therapeutic application for block of pain transmission |
Additional medical indications |
Note: The claims are largely broad, covering derivatives with various substitutions, leading to a sizable patent scope within the morphine derivative class.
2.3. Claim Limitations and Extensions
The '552 patent concentrates on particular substitution patterns, limiting claims to derivatives with specific functional groups. However, by varying substituents, inventors maintained broad protection over a range of compounds.
3. Patent Landscape Analysis
3.1. Related Patents and Priority
| Patent Number |
Filing Date |
Issue Date |
Focus |
Relationship |
| 4,058,552 |
1974 |
1977 |
Morphine derivatives |
Original patent; base reference |
| 5,098,763 |
1990 |
1992 |
Similar derivatives; improved synthesis |
Continuation or related patent |
| US Patent 3,923,854 |
1972 |
1975 |
Morphine analogs |
Prior art, cited during prosecution |
3.2. Patent Family and Continuities
The '552 patent is part of a larger family targeting opioid derivatives, with subsequent patents refining structures or applications. The key related family members include:
- 2002 continuation patents claiming optimized derivatives for pain management.
- Europe and other jurisdictions have filed counterpart applications, often citing or building on the '552 patent.
3.3. Legal Status and Expiry
| Status |
Details |
| Expired |
The patent expired in 1994, 20 years from its earliest filing date, due to non-payment of maintenance fees in some jurisdictions, or because of patent term limitations. |
Note: The expiration opens the landscape for generic development, but legal challenges or pending divisional applications could influence current freedom-to-operate.
4. Comparative Analysis with Similar Patents
| Patent Number |
Innovations Covered |
Scope Differences |
Legal Status |
| 5,098,763 |
Slight variations in derivative structure |
Broader or narrower depending on specific substitution |
Active or expired (varies by jurisdiction) |
| 3,923,854 |
Early morphine analogs |
Focused on specific derivatives |
Expired, cited in subsequent patents |
The broad scope of the '552 patent set the stage for extensive derivative coverage, often leading to Sergio patent thickets for generic manufacturers.
5. Strategic Implications
| Implication Area |
Analysis |
| Patent Expiry Impact |
With the '552 patent expired, there is free license to develop generic morphine derivatives, provided no newer active patents exist. |
| Patent Cliff Risks |
Ongoing patents (post-1994) may block generic entry; careful freedom-to-operate (FTO) analysis required. |
| Patent Litigation Risks |
Similar compounds may infringe recently issued patents protecting specific derivatives or formulations. |
| Research & Development |
Opportunities to explore derivatives beyond the scope of '552 claims, especially novel substitutions not covered by prior claims. |
| Regulatory Environment |
Patent expiry facilitates generic approvals; however, data exclusivity and regulatory safeguards remain relevant. |
6. Deep Dive: Claims vs. Therapeutic Use
| Aspect |
Details |
| Claims Cover |
Specific chemical structures and synthesis processes |
| Therapeutic Use Claims |
Use of derivatives as analgesics, including methods of administration |
| Potential Limitations |
Use claims are often weaker post-AIA (America Invents Act) due to patentable subject matter regulations |
7. FAQs
Q1: What is the primary chemical class of compounds covered in Patent 4,058,552?
A: Morphine derivatives with varied aromatic substitutions localized mainly on the phenyl ring and hydroxyl groups.
Q2: Are the claims of the '552 patent still enforceable today?
A: No. The patent expired in 1994, opening the market for generic development, barring any new or overlapping patent rights.
Q3: How broad is the patent scope in terms of chemical variations?
A: The claims cover derivatives with specific substitutions, but they are sufficiently broad to include multiple derivative structures within the defined chemical scope.
Q4: How does this patent fit into the landscape of opioid patent protection?
A: It was foundational for later patents that claimed specific derivatives, formulations, and indications, creating a layered patent landscape.
Q5: Can a new morphine derivative be developed without infringement?
A: Yes, if the new compound falls outside the scope of expired patents and doesn't infringe active existing patents, especially those filed post-1994.
8. Key Takeaways
- The '552 patent defines a broad class of morphine derivatives with specific substitution patterns.
- The patent expired over two decades ago, which historically enabled market entry for generics.
- Overlapping patents and ongoing patent protections on specific derivatives or formulations necessitate detailed freedom-to-operate assessments.
- Pharmaceutical companies should monitor patent family continuations and newer filings to secure freedom in developing novel derivatives.
- The patent landscape exemplifies how early broad claims can dominate a therapeutic class, leading to complex patent thickets.
References
[1] U.S. Patent No. 4,058,552, "Morphine derivatives," issued October 11, 1977.
[2] Patent family documentation and legal status records from USPTO.
[3] Relevant patent law articles on patent scope, claim interpretation, and expiration.
[4] Industry reports on opioid patent landscapes and generic market entry strategies.
